Biomark Diagnostics Inc. (CSE:BUX)

Biomark Diagnostics Income Statement

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	0.15	0.16	0.15	0.04	-
Revenue Growth (YoY)	-5.52%	6.34%	249.38%	-	-
Gross Profit	0.15	0.16	0.15	0.04	-
Selling, General & Admin	0.74	0.75	0.73	0.65	0.9
Research & Development	0.7	0.65	0.55	0.5	0.12
Operating Expenses	2.2	1.87	1.99	1.33	1.03
Operating Income	-2.05	-1.71	-1.84	-1.28	-1.03
Interest Expense	-0.06	-0.06	-0.11	-0.04	-
Interest & Investment Income	0	0	0	-	0
Currency Exchange Gain (Loss)	-0	0	-	-0	-0.01
Other Non Operating Income (Expenses)	0.18	0.34	0.11	-0.13	-0.06
EBT Excluding Unusual Items	-1.93	-1.43	-1.84	-1.45	-1.1
Other Unusual Items	-	-	-	-	0
Pretax Income	-1.93	-1.43	-1.84	-1.45	-1.09
Net Income	-1.93	-1.43	-1.84	-1.45	-1.09
Net Income to Common	-1.93	-1.43	-1.84	-1.45	-1.09
Shares Outstanding (Basic)	91	85	83	78	73
Shares Outstanding (Diluted)	91	85	83	78	73
Shares Change (YoY)	6.67%	2.97%	6.22%	6.31%	2.82%
EPS (Basic)	-0.02	-0.02	-0.02	-0.02	-0.01
EPS (Diluted)	-0.02	-0.02	-0.02	-0.02	-0.01
Free Cash Flow	-1.1	-0.99	-0.92	-1.26	-0.81
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.02	-0.01
Gross Margin	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-1327.45%	-1046.96%	-1198.95%	-2922.50%	-
Profit Margin	-1249.73%	-874.52%	-1200.21%	-3309.36%	-
Free Cash Flow Margin	-711.12%	-604.65%	-599.20%	-2875.13%	-
EBITDA	-2.03	-1.7	-1.83	-1.28	-1.03
D&A For EBITDA	0.02	0.01	0.01	0.01	0
EBIT	-2.05	-1.71	-1.84	-1.28	-1.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.